- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
New Immunooncology Drug from Incyte Raises Immense Interest at ASCO
Excitement at ASCO 2014 on Incyte's new immunoonoclogy drug candidate, INCB024360 ('360),in melanoma, despite a small 'n'.
We just got our first look at the clinical activity of
(INCY)
immuno-oncology candidate INCB024360 ('360) dosed at 50 mg and combined with
(BMY)
Yervoy in melanoma patients
Incyte'sBristol-Myers Squibb's
Four immunotherapy-naive melanoma patients dosed with 50 mg of '360 plus Yervoy yielded 1 complete response and 1 partial response for an overall response
of 50%. A third patient reported stable disease so the disease control rate was 75%. The
.
Story:
rateIncyte press release and poster can be found herehttp://bit.ly/1pP7ZeT
Source: The Street
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
